The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. [PDF]
Cancer Immunol Immunother, 2018 Anichini A +3 more
europepmc +1 more source
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? [PDF]
Cancer Immunol Immunother, 2015 Calabrò L +6 more
europepmc +1 more source
Cholesterol metabolites and tumor microenvironment: the road towards clinical translation. [PDF]
Cancer Immunol Immunother, 2016 Raccosta L +5 more
europepmc +1 more source
T cell responses to tumor: how dominant assumptions on immune activity led to a neglect of pathological functions, and how evolutionary considerations can help identify testable hypotheses for improving immunotherapy. [PDF]
Cancer Immunol Immunother, 2018 Kallikourdis M.
europepmc +1 more source
Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies. [PDF]
Cancer Immunol Immunother, 2015 Castelli C +5 more
europepmc +1 more source
Overcoming the toxicity hurdles of genetically targeted T cells. [PDF]
Cancer Immunol Immunother, 2015 Casucci M +3 more
europepmc +1 more source
Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. [PDF]
Cancer Immunol Immunother, 2018 Petitprez F +6 more
europepmc +1 more source
[Acute fibrinous and organizing pneumonia]. [PDF]
Rev Port Pneumol (2006), 2010 Santos C +3 more
europepmc +2 more sources
Armed antibodies for cancer treatment: a promising tool in a changing era. [PDF]
Cancer Immunol Immunother, 2015 Danielli R +7 more
europepmc +1 more source